Neoadjuvant anlotinib combined with PD-1 blockade therapy remodeling the microenvironment in advanced non-small cell lung cancer
Ontology highlight
ABSTRACT: Neoadjuvant anlotinib combined with PD-1 blockade therapy can prolong the survival of patients, but the underlying mechanisms for the failure of patients to benefit from combination therapy remain to be explored. To explore the mechanism of drug resistance and predict patient response, we performed scRNA-seq from 6 NSCLC patients, including 3 post-treatment patients with major pathological response (MPR), and 3 Non-MPR patients to observe and analyze the dynamic changes of immune cells, stromal cells and cancer cells from the NSCLC patients who received neoadjuvant anlotinib combined with PD-1 blockade therapy and verified in an independent cohort.
ORGANISM(S): Homo sapiens
PROVIDER: GSE291670 | GEO | 2025/03/31
REPOSITORIES: GEO
ACCESS DATA